RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban
There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.
Signal weather
Stable
The story has moved beyond the first headline and now acts as a reliable context anchor.
The Food and Drug Administration on Wednesday announced meeting dates for advisors to discuss lifting restrictions on 12 unproven peptides that the agency deemed to pose significant safety risks in 2023. The meetings are scheduled for two days in July, with another in February 2027. The scheduled meetings do not appear to be accompanied by any significant new safety or efficacy data for FDA advisors to discuss. Rather, the FDA is being pushed to ease restrictions on these peptides at the behest of anti-vaccine Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of the unproven drugs. Peptide drugs are simply those made of short chains of amino acids linked by peptide bonds. FDA-approved peptide drugs include insulin for diabetes and GLP-1 drugs for obesity. But online, peptides typically refer to unproven drugs, often given by injection, that are peddled without evidence as treating various conditions, reversing aging, and improving appearance. This category has seen a boom in popularity among wellness influencers, including Kennedy and many of his allies. Read full article Comments
Stay on the signal
Follow RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban
Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.
Story map
Understand this topic fast
A quick entry into the story: why it matters now, who is involved, and where to go next for context.
Why it matters now
Topic constellation
Open the live map for this story
See which entities, story threads, sources, and follow-up articles shape this story right now.
Click nodes to continue
Entity pages
Story timeline
Continue with this story
A short sequence of events and follow-up stories to understand the arc quickly.
How reliable this looks
Signal and trust for Ars Technica
This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.
Reliability
92
Freshness
100
Sources in storyline
1
Related articles
More stories that share tags, source, or category context.
PeopleSoft 0-day affecting hundreds of organizations steals gigabytes of data
Vulnerability in the Oracle-owned PeopleSoft software is about as critical as they come.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Controversial FISA spying law expires tonight. The spying will continue.
Section 702 of FISA to expire tonight, but certification lasts until March 2027.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Here's what Jeff Bezos' new startup Prometheus will do
It isn't the only startup tackling physical AI, but it's one of the best-funded.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Have politics finally come for the National Academies of Science?
A pending report on climate attribution may be setting the stage for conflict.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
More from Ars Technica
Fresh reporting and follow-up coverage from the same newsroom.
PeopleSoft 0-day affecting hundreds of organizations steals gigabytes of data
Vulnerability in the Oracle-owned PeopleSoft software is about as critical as they come.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Controversial FISA spying law expires tonight. The spying will continue.
Section 702 of FISA to expire tonight, but certification lasts until March 2027.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Here's what Jeff Bezos' new startup Prometheus will do
It isn't the only startup tackling physical AI, but it's one of the best-funded.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Have politics finally come for the National Academies of Science?
A pending report on climate attribution may be setting the stage for conflict.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.